{
    "id": "antidiabetic_mechanisms_matrixMatch_v1",
    "type": "matrixMatch",
    "matrixType": "multipleResponse",
    "stem": "The nurse is providing education to a client on newer antidiabetic medications. For each medication class, select the correct mechanism(s) of action and primary side effect(s).",
    "rows": [
        {
            "id": "r1",
            "text": "GLP-1 Receptor Agonists (e.g., Semaglutide)"
        },
        {
            "id": "r2",
            "text": "SGLT2 Inhibitors (e.g., Canagliflozin)"
        },
        {
            "id": "r3",
            "text": "Sulfonylureas (e.g., Glyburide)"
        },
        {
            "id": "r4",
            "text": "Biguanides (Metformin)"
        }
    ],
    "columns": [
        {
            "id": "c1",
            "text": "Promotes glucose excretion via kidneys"
        },
        {
            "id": "c2",
            "text": "Slows gastric emptying & suppresses appetite"
        },
        {
            "id": "c3",
            "text": "Inhibits liver glucose production"
        },
        {
            "id": "c4",
            "text": "Stimulates pancreas to release insulin"
        },
        {
            "id": "c5",
            "text": "High risk of Hypoglycemia"
        }
    ],
    "correctAnswers": {
        "r1": [
            "c2"
        ],
        "r2": [
            "c1"
        ],
        "r3": [
            "c4",
            "c5"
        ],
        "r4": [
            "c3"
        ]
    },
    "pedagogy": {
        "bloomLevel": "analyze",
        "cjmmStep": "takeAction",
        "nclexCategory": "Pharmacological and Parenteral Therapies",
        "difficulty": 4,
        "topicTags": [
            "Pharmacology",
            "Diabetes",
            "Endocrine"
        ]
    },
    "rationale": {
        "correct": "Modern diabetes management targets multiple pathways. (r1) GLP-1s mimic incretins, slowing digestion and increasing satiety. (r2) SGLT2s block reabsorption in the proximal tubule. (r3) Sulfonylureas are 'secretagogues' that force insulin release, carrying a high hypoglycemia risk. (r4) Metformin's primary role is reducing hepatic glucose output.",
        "incorrect": "Metformin and SGLT2 inhibitors have a very low risk of hypoglycemia when used alone as they do not force insulin release.",
        "answerBreakdown": [],
        "clinicalPearls": [
            "GLP-1 receptor agonists are often used for weight loss and cardiovascular protection in Type 2 Diabetes."
        ],
        "questionTrap": {
            "trap": "The 'Hypoglycemia' Generalization",
            "howToOvercome": "Not all diabetes drugs cause hypoglycemia. Only Insulin, Sulfonylureas, and Meglitinides carry a primary hypoglycemia risk. Metformin and SGLT2s usually do NOT."
        },
        "mnemonic": {
            "title": "G-S-M",
            "expansion": "GLP (Gut/Gastric), SGLT (Sugar Leaking Through), Metformin (Manufacturing inhibitor - Liver)."
        },
        "reviewUnits": [
            {
                "heading": "Antidiabetic Pharmacotherapy",
                "body": "Nurses must counsel patients on timing and side effects. Sulfonylureas require food intake. SGLT2s require fungal infection monitoring. GLP-1s require GI tolerance monitoring.",
                "source": "ADA Standards of Care 2026"
            }
        ]
    },
    "scoring": {
        "method": "dichotomousPerWeight",
        "maxPoints": 5
    }
}